Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
290 studies found for:    cytarabine | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Condition: Leukemia
Intervention: Drug: Ara-c
2 Recruiting LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: LY2510924;   Drug: Idarubicin;   Drug: Cytarabine
3 Recruiting LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Drug: LY2606368
4 Not yet recruiting Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Condition: Hematologic Malignancy
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Drug: Erwinase
5 Recruiting AC220 With 5-Aza or Low Dose Cytarabine
Condition: Leukemia
Interventions: Drug: Quizartinib;   Drug: Cytarabine;   Drug: AZA
6 Recruiting Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Conditions: Acute Myeloid Leukemia;   Core-Binding Factor
Interventions: Drug: Fludarabine;   Drug: Cytarabine
7 Recruiting Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
8 Recruiting A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Condition: Acute Leukemia
Interventions: Drug: PTX-200;   Drug: Cytarabine
9 Recruiting Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Condition: AML
Interventions: Drug: Daunomycin and Cytarabine (DA Regimen);   Drug: Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)
10 Recruiting Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Condition: Langerhans Cell Histiocytosis
Interventions: Drug: Cytarabine;   Drug: Vinblastine/prednisone
11 Not yet recruiting The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Interventions: Drug: Bortezomib;   Drug: Fludarabine;   Drug: Cytarabine
12 Recruiting Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: BGB324;   Drug: Cytarabine
13 Recruiting Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Myeloid Sarcoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
Interventions: Drug: Cytarabine;   Drug: Vosaroxin
14 Recruiting Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Condition: Acute Myeloid Leukemia
Intervention: Drug: Lovastatin and Cytarabine
15 Recruiting Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
Conditions: Acute Myeloid Leukemia;   Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions: Drug: Ficlatuzumab;   Drug: Cytarabine
16 Recruiting A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Neoplasms, Leukemia, Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Drug: Idasanutlin;   Other: Placebo
17 Recruiting A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Drug: Venetoclax;   Drug: Cytarabine
18 Recruiting A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Condition: Acute Myeloid Leukemia, Relapsed, Adult
Interventions: Drug: F16IL2;   Drug: cytarabine
19 Recruiting Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndromes
Interventions: Drug: Phase 1 - OXi4503;   Drug: Phase 1 - OXi4503 + cytarabine;   Drug: Phase 2 - OXi4503 + cytarabine
20 Recruiting Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.